References for: association

Full identifier: http://purl.org/np/RA71ceCS4_CTtsrd78Wo_2ODmTGSTzMZHM7e79vfYjIzQ#association

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Psychostimulants were associated with statistically significant improvement in depressive symptoms in major depressive disorder (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.13-1.78; P = 0.003) and bipolar disorder (OR, 1.42; 95% CI, 1.13-1.78; P = 0.003). Efficacy outcomes differed across the psychostimulants evaluated as a function of response rates: ar/modafinil (OR, 1.47; 95% CI, 1.20-1.81; P = 0.0002); dextroamphetamine (OR, 7.11; 95% CI, 1.09-46.44; P = 0.04); lisdexamfetamine dimesylate (OR, 1.21; 95% CI, 0.94-1.56; P = ns); methylphenidate (OR, 1.49; 95% CI, 0.88-2.54; P = ns). Efficacy outcomes also differed between agents used as adjunctive therapy (OR, 1.39; 95% CI, 1.19-1.64) or monotherapy (OR, 2.25; 95% CI, 0.67-7.52).
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-26T14:50:07.672Z